Literature DB >> 9150154

Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

S Håkansson1, O Johannsson, U Johansson, G Sellberg, N Loman, A M Gerdes, E Holmberg, N Dahl, N Pandis, U Kristoffersson, H Olsson, A Borg.   

Abstract

Previous studies of high-risk breast cancer families have proposed that two major breast cancer-susceptibility genes, BRCA1 and BRCA2, may account for at least two-thirds of all hereditary breast cancer. We have screened index cases from 106 Scandinavian (mainly southern Swedish) breast cancer and breast-ovarian cancer families for germ-line mutations in all coding exons of the BRCA1 and BRCA2 genes, using the protein-truncation test, SSCP analysis, or direct sequencing. A total of 24 families exhibited 11 different BRCA1 mutations, whereas 11 different BRCA2 mutations were detected in 12 families, of which 3 contained cases of male breast cancer. One BRCA2 mutation, 4486delG, was found in two families of the present study and, in a separate study, also in breast tumors from three unrelated males with unknown family history, suggesting that at least one BRCA2 founder mutation exists in the Scandinavian population. We report 1 novel BRCA1 mutation, eight additional cases of 4 BRCA1 mutations described elsewhere, and 11 novel BRCA2 mutations (9 frameshift deletions and 2 nonsense mutations), of which all are predicted to cause premature truncation of the translated products. The relatively low frequency of BRCA1 and BRCA2 mutations in the present study could be explained by insufficient screening sensitivity to the location of mutations in uncharacterized regulatory regions, the analysis of phenocopies, or, most likely, within predisposed families, additional uncharacterized BRCA genes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9150154      PMCID: PMC1712420     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  27 in total

1.  Transcriptional activation by BRCA1.

Authors:  M S Chapman; I M Verma
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

2.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

Authors:  R Wooster; S L Neuhausen; J Mangion; Y Quirk; D Ford; N Collins; K Nguyen; S Seal; T Tran; D Averill
Journal:  Science       Date:  1994-09-30       Impact factor: 47.728

3.  Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2.

Authors:  T R Rebbeck; F J Couch; J Kant; K Calzone; M DeShano; Y Peng; K Chen; J E Garber; B L Weber
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

4.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

Authors:  Y Miki; J Swensen; D Shattuck-Eidens; P A Futreal; K Harshman; S Tavtigian; Q Liu; C Cochran; L M Bennett; W Ding
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

5.  Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.

Authors:  M Schutte; L T da Costa; S A Hahn; C Moskaluk; A T Hoque; E Rozenblum; C L Weinstein; M Bittner; P S Meltzer; J M Trent
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

6.  Hypophyseal tumor and gynecomastia preceding bilateral breast cancer development in a man.

Authors:  H Olsson; P Alm; U Kristoffersson; M Landin-Olsson
Journal:  Cancer       Date:  1984-05-01       Impact factor: 6.860

7.  Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.

Authors:  L S Friedman; E A Ostermeyer; C I Szabo; P Dowd; E D Lynch; S E Rowell; M C King
Journal:  Nat Genet       Date:  1994-12       Impact factor: 38.330

8.  A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening.

Authors:  D Shattuck-Eidens; M McClure; J Simard; F Labrie; S Narod; F Couch; K Hoskins; B Weber; L Castilla; M Erdos
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

9.  Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer.

Authors:  J van den Berg; O Johannsson; S Håkansson; H Olsson; A Borg
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

10.  Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.

Authors:  A M Cleton-Jansen; N Collins; S R Lakhani; J Weissenbach; P Devilee; C J Cornelisse; M R Stratton
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

View more
  44 in total

1.  The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study.

Authors:  J F Stratton; D Thompson; L Bobrow; N Dalal; M Gore; D T Bishop; I Scott; G Evans; P Daly; D F Easton; B A Ponder
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.

Authors:  B H Spain; C J Larson; L S Shihabuddin; F H Gage; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

3.  Frequencies of single-nucleotide polymorphisms and mutations in the BRCA1 gene in patients with hereditary breast or ovarian cancer.

Authors:  A V Karpukhin; N I Pospekhova; L N Lubchenko; A N Loginova; E V Khomich; A V Budilov; A S Sergeev; V M Zakhar'ev; R F Gar'kavtseva; E K Ginter
Journal:  Dokl Biol Sci       Date:  2002 Mar-Apr

4.  Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.

Authors:  S L Neuhausen; A K Godwin; R Gershoni-Baruch; E Schubert; J Garber; D Stoppa-Lyonnet; E Olah; B Csokay; O Serova; F Lalloo; A Osorio; M Stratton; K Offit; J Boyd; M A Caligo; R J Scott; A Schofield; E Teugels; M Schwab; L Cannon-Albright; T Bishop; D Easton; J Benitez; M C King; B A Ponder; B Weber; P Devilee; A Borg; S A Narod; D Goldgar
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

5.  Population genetics of BRCA1 and BRCA2.

Authors:  C I Szabo; M C King
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

6.  Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.

Authors:  J Vallon-Christersson; C Cayanan; K Haraldsson; N Loman; J T Bergthorsson; K Brøndum-Nielsen; A M Gerdes; P Møller; U Kristoffersson; H Olsson; A Borg; A N Monteiro
Journal:  Hum Mol Genet       Date:  2001-02-15       Impact factor: 6.150

7.  Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

Authors:  P N Tonin; A M Mes-Masson; P A Futreal; K Morgan; M Mahon; W D Foulkes; D E Cole; D Provencher; P Ghadirian; S A Narod
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

8.  BRCA1 and BRCA2 mutations in Scotland and Northern Ireland.

Authors: 
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

9.  Familial breast cancer: an investigation into the outcome of treatment for early stage disease.

Authors:  D Eccles; P Simmonds; J Goddard; M Coultas; S Hodgson; F Lalloo; G Evans; N Haites
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

10.  Clinicopathological study of male breast carcinoma: 24 years of experience.

Authors:  Parveen Shah; Irfan Robbani; Omar Shah
Journal:  Ann Saudi Med       Date:  2009 Jul-Aug       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.